With so many individuals at risk for HIV, why aren’t more being prescribed a PrEP medication?
Learn about HIV prevalence and risk factors.
Uptake of PrEP use in the United States remains low despite significant HIV risk1
Nearly
1 million
cisgender males had an indication
for a PrEP medication by 2020
However, only
26%
of these patients were prescribed
a PrEP medication2
Among MSM diagnosed with HIV in 2019,3
38%
were Black MSM
and
32%
were Latino MSM
Yet, in a 2017 CDC study of PrEP use among MSM at risk (n=4056), only4
6%
were Black MSM
and
8%
were Latino MSM
Transgender women who are at risk for HIV may benefit from PrEP medication
A study conducted between 2019 and 2020 in Atlanta, Los Angeles, New Orleans, New York City, Philadephia, Seattle, and San Francisco (n=1608) found that5
42%
(n=659/1561) of TGW were HIV positive
and only
32%
(n=288/902)
of HIV-negative TGW
Help meet HIV risk head-on—talk to your appropriate patients about DESCOVY FOR PrEP®.
CDC=Centers for Disease Control and Prevention; MSM=men who have sex with men; TGW=transgender women (who have sex with men).